Login
Zynerba Pharmaceuticals NASDAQ: ZYNE
Zynerba’s mission is to develop next-generation transdermally-delivered cannabinoid therapeutics to help address significant unmet medical needs and improve the lives of patients with rare and near-rare neuropsychiatric conditions
| Name | Zynerba Pharmaceuticals |
| Ticker | ZYNE |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Cannabinoid Therapeutics |
|
Price
52W Low/High |
4.03
3.23 / 8.76 |
| Momentum | Weak Down |
| Market cap | 119 M |
| 1Y Total Return |
3.33%
Weak |
| 1Y Volatility |
123.28%
High Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
Zynerba’s mission is to develop next-generation transdermally-delivered cannabinoid therapeutics to help address significant unmet medical needs and improve the lives of patients with rare and near-rare neuropsychiatric conditions
Details
| Ticker | ZYNE |
| Name | Zynerba Pharmaceuticals |
| ISIN | US98986X1090 |
| CUSIP | 98986X109 |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Cannabinoid Therapeutics |
| Country | USA |
| Currency | U.S. Dollar |
Share as of 4/15/21
| Close Price | 4.03 |
| 52W Low/High | 3.23 / 8.76 |
| Market cap | 119 M |
| 1Y Total Return |
3.33%
Weak |
| 1Y Volatility |
123.28%
High Risk |
| Beta | 3.18 |
| PE (trailing) | - |
| 12M Dividends | - |
| Last Dividend Date | - |
| Dividend Yield | - |
Fin. Strength
| Net Profit Margin | - |
| Cash from Op. / Cur. Liabilities | -2.97 |
| Diluted Earnings / Share | -1.90 |
| ROE | - |
| ROIC | -1,548.7% |
| Price / Revenue | - |
| Price / Book | 1.8 |
| Price / CF | -2.6 |
| Current Ratio | 5.3 |
| Cur.Liabilities / Tot.Liabilities | 1.0 |
| Financial Leverage | 0.00 |
| in Mils USD |
rolling-year up to December
|
||||||
|---|---|---|---|---|---|---|---|
| Income Statement | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Revenue |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Gross Profit |
-
|
-
|
0
|
-
|
0
|
0
|
|
| R&D |
36
|
20
|
27
|
23
|
17
|
7
|
|
| EBITDA |
-51
|
-33
|
-40
|
-32
|
-23
|
-12
|
|
| Operating Income |
-52
|
-34
|
-40
|
-33
|
-23
|
-13
|
|
| Net Income exc. Extra |
-
|
-
|
-
|
-
|
-
|
-
|
|
| per Share | |||||||
| Diluted avg Shares |
27
|
22
|
15
|
13
|
9
|
4
|
|
| EPS exc. Extra |
-1.90
|
-1.50
|
-2.61
|
-2.48
|
-2.58
|
-2.82
|
|
| Dividend |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Div. Yield (an.) |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Balance Sheet | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Total Assets |
74
|
88
|
67
|
69
|
37
|
44
|
|
| Cash, Eq & Invt ShortTerm |
59
|
70
|
60
|
63
|
31
|
42
|
|
| Total Current Assets |
73
|
87
|
67
|
68
|
36
|
43
|
|
| Total Non-Current Assets |
1
|
1
|
0
|
1
|
0
|
0
|
|
| Intangibles |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Liabilities |
14
|
12
|
10
|
8
|
7
|
4
|
|
| Total Current Liabilities |
14
|
12
|
10
|
7
|
7
|
4
|
|
| Long Term Debt |
0
|
0
|
0
|
1
|
0
|
0
|
|
| Shareholder equity |
60
|
76
|
58
|
61
|
30
|
40
|
|
| Cash Flow | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Cash from Operations |
-41
|
-35
|
-32
|
-26
|
-20
|
-10
|
|
| Depreciation |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Cash from Investing |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Capex |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Cash from Financing |
31
|
45
|
30
|
58
|
10
|
42
|
|
| Stock Issued |
32
|
47
|
33
|
58
|
10
|
42
|
|
| Debt (LT) Issued |
-1
|
-2
|
-3
|
0
|
0
|
0
|
|
| Free Cash Flow |
-50
|
-31
|
-38
|
-32
|
-20
|
-12
|
|
| Ratios | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Net Profit Margin |
-
|
-
|
-
|
-
|
-
|
-
|
|
| NCFO / Op.Income |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Current Ratio |
5.3
|
7.2
|
6.9
|
9.2
|
5.2
|
11.0
|
|
| Financial Leverage D/E |
0.00
|
0.00
|
0.00
|
0.00
|
0.00
|
0.00
|
|
| Return on Capital Avg |
-1,548.7%
|
-1,892.7%
|
-
|
-
|
-
|
-
|
|
| Return on Shareholder Equity |
-
|
-
|
-
|
-
|
-
|
-
|
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available